Last year we gathered 250+ industry and academic leaders. At this year’s 4th Annual Gene Therapy for Neurological Disorders Summit, we are set to unite 300+ Clinical & Pre clinical, Safety, Neuronal, Pharmacology, Bioanalytical and Toxicology experts from the fields leading companies. From extensive research with the leading gene therapy drug developers targeting the CNS, we are aware that biopharma are actively seeking to collaborate with organizations that can help them solve several key challenges holding back progress in the market.
For partnership opportunities to market your CNS or gene therapy expertise to this niche audience of senior pioneers,
get in touch to find out more about our bespoke packages available this December.